ERBB2 and breast carcinoma: The first group was represented by Hormone positive/HER2 (HR+/HER2) negative breast cancer patients (12 women), the second by HER2 positive BC patients (4 women) and finally the third by Triple negative BC (TNBC) patients (4 women).